EP2389189A4 - Verfahren zur prävention und behandlung von diastolischer dysfunktion mit einem mimetischen apolipoprotein a1 (apoa1)-peptid/phospholipid-komplex - Google Patents

Verfahren zur prävention und behandlung von diastolischer dysfunktion mit einem mimetischen apolipoprotein a1 (apoa1)-peptid/phospholipid-komplex

Info

Publication number
EP2389189A4
EP2389189A4 EP10733186A EP10733186A EP2389189A4 EP 2389189 A4 EP2389189 A4 EP 2389189A4 EP 10733186 A EP10733186 A EP 10733186A EP 10733186 A EP10733186 A EP 10733186A EP 2389189 A4 EP2389189 A4 EP 2389189A4
Authority
EP
European Patent Office
Prior art keywords
apoa1
prevention
treatment
diastolic dysfunction
mimetic peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10733186A
Other languages
English (en)
French (fr)
Other versions
EP2389189A1 (de
Inventor
Jean-Claude Tardif
David Busseuil
Eric Rheaume
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut de Cardiologie de Montreal
Original Assignee
Institut de Cardiologie de Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut de Cardiologie de Montreal filed Critical Institut de Cardiologie de Montreal
Publication of EP2389189A1 publication Critical patent/EP2389189A1/de
Publication of EP2389189A4 publication Critical patent/EP2389189A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP10733186A 2009-01-23 2010-01-25 Verfahren zur prävention und behandlung von diastolischer dysfunktion mit einem mimetischen apolipoprotein a1 (apoa1)-peptid/phospholipid-komplex Withdrawn EP2389189A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20205109P 2009-01-23 2009-01-23
US20219109P 2009-02-05 2009-02-05
PCT/CA2010/000108 WO2010083611A1 (en) 2009-01-23 2010-01-25 Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex

Publications (2)

Publication Number Publication Date
EP2389189A1 EP2389189A1 (de) 2011-11-30
EP2389189A4 true EP2389189A4 (de) 2012-12-19

Family

ID=42355467

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10733186A Withdrawn EP2389189A4 (de) 2009-01-23 2010-01-25 Verfahren zur prävention und behandlung von diastolischer dysfunktion mit einem mimetischen apolipoprotein a1 (apoa1)-peptid/phospholipid-komplex

Country Status (3)

Country Link
EP (1) EP2389189A4 (de)
CA (1) CA2788223A1 (de)
WO (1) WO2010083611A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120021982A1 (en) * 2009-01-23 2012-01-26 Jean-Claude Tardif Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction
SI2396017T1 (sl) 2009-02-16 2015-12-31 Cerenis Therapeutics Holding Sa Mimika apolipoproteina A-1
AR082644A1 (es) 2010-08-30 2012-12-19 Hoffmann La Roche Tetranectina-apolipoproteina a-i, particulas lipidicas que la contiene y utilizacion de la misma relacionado con el metabolismo de los lipidos y las enfermedades cardiovasculares
RU2014108240A (ru) 2011-08-25 2015-09-27 Ф. Хоффманн-Ля Рош Аг Укороченный тетранектин-аполипопротеин а-i гибридный белок, содержащая его липидная частица и их применения
US9402975B2 (en) 2011-08-31 2016-08-02 Becton, Dickinson And Company Systems and methods to increase rigidity and snag-resistance of catheter tip

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
BR0009520A (pt) 1999-04-01 2002-06-11 Esperion Therapeutics Inc Composto, método para sintetizar o mesmo, composição, metódos para o tratramento ou prevenção, em um paciente, de doença cardiovascular, dislipidemia, dislipoproteinemia, distúrbio de metabolismo de glucose, doença de alzheimer, sìndrome x ou sìndrome metabólica, septicemia, distúrbio trombótico, distúrbio associado com receptor ativado por proliferador de peroxissoma, obesidade, pancreatite, hipertensão, doença renal, câncer, inflamação, impotência, para reduzir o teor de gordura de carne de gado bovino, e, para reduzir o teor de colesterol de ovos de aves
CA2653840A1 (en) * 2006-06-01 2007-12-06 Institut De Cardiologie De Montreal Use of a peptide/phospholipid complex acting as a reverse lipid transport agonist for treatment of valvular stenosis

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BEYERBACHT H P ET AL: "Aortic valve replacement in patients with aortic valve stenosis improves myocardial metabolism and diastolic function.", June 2001, RADIOLOGY JUN 2001 LNKD- PUBMED:11376247, VOL. 219, NR. 3, PAGE(S) 637 - 643, ISSN: 0033-8419, XP002686474 *
BUSSEUIL D ET AL: "Regression of aortic valve stenosis by ApoA-I mimetic peptide infusions in rabbits.", June 2008, BRITISH JOURNAL OF PHARMACOLOGY JUN 2008 LNKD- PUBMED:18414386, VOL. 154, NR. 4, PAGE(S) 765 - 773, ISSN: 0007-1188, XP002686476 *
BUSSEUIL DAVID ET AL: "[A new type of medical treatment could lead to regression of aortic valve stenosis].", August 2008, MÉDECINE SCIENCES : M/S 2008 AUG-SEP LNKD- PUBMED:18789203, VOL. 24, NR. 8-9, PAGE(S) 675 - 676, ISSN: 0767-0974, XP002686475 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; July 2000 (2000-07-01), RISTIC-ANDJELKOV A ET AL: "[Echocardiographic evaluation of left ventricular diastolic function in patients with aortic valve stenosis].", XP002686473, Database accession no. NLM11521465 *
MANDINOV L ET AL: "Diastolic heart failure", CARDIOVASCULAR RESEARCH, OXFORD UNIVERSITY PRESS, GB, vol. 45, 1 January 2000 (2000-01-01), pages 813 - 825, XP002903841, ISSN: 0008-6363, DOI: 10.1016/S0008-6363(99)00399-5 *
MARCHESI ET AL: "Apolipoprotein A-IMilano/POPC complex attenuates post-ischemic ventricular dysfunction in the isolated rabbit heart", ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, IE, vol. 197, no. 2, 22 October 2007 (2007-10-22), pages 572 - 578, XP022559364, ISSN: 0021-9150, DOI: 10.1016/J.ATHEROSCLEROSIS.2007.08.028 *
OLCAY AKSOY ET AL: "Do Bisphosphonates Slow the Progression of Aortic Stenosis?", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 59, no. 16, 2 January 2012 (2012-01-02), pages 1452 - 1459, XP028406141, ISSN: 0735-1097, [retrieved on 20120303], DOI: 10.1016/J.JACC.2012.01.024 *
See also references of WO2010083611A1 *

Also Published As

Publication number Publication date
EP2389189A1 (de) 2011-11-30
CA2788223A1 (en) 2010-07-29
WO2010083611A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
HK1215182A1 (zh) 包含彈性蛋白樣肽的治療劑
HK1208237A1 (en) Methods for the treatment of gout
HK1217293A1 (zh) 預防或治療心力衰竭的方法
ZA201204625B (en) Analogues for the treatment or prevention of flavivirus infections
GB2464906B (en) Cryogenic treatment of gas
IL218116A (en) Different peptides that have active and isotope from the gut containing elastin-like peptides
IL217503A0 (en) Benzimidazole analogues for the treatment or prevention of flavivirus infections
EP2068768A4 (de) Verfahren und system zur verbesserung der diastolischen herzfunktion
EP2097012A4 (de) Vorrichtungen und verfahren zur behandlung von herzversagen
EP2032131A4 (de) Behandlungsverfahren
EP2352515A4 (de) Verfahren zur behandlung von hämophilie
EP1995254A4 (de) Verfahren zur herstellung von peptiden
HK1149322A1 (en) Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
HK1155075A1 (en) Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
GB0610746D0 (en) Method of treatment
HK1167148A1 (en) Method for the preparation of cyclopeptides
EP2717902A4 (de) Verwendung modifizierter vasoaktiver darmpeptide bei der behandlung von bluthochdruck
EP1996609A4 (de) Verfahren zur herstellung von glycopeptiden
EP2389189A4 (de) Verfahren zur prävention und behandlung von diastolischer dysfunktion mit einem mimetischen apolipoprotein a1 (apoa1)-peptid/phospholipid-komplex
EP2411042A4 (de) Gewebe-kallikrein zur behandlung von pankreaszellendysfunktionen
EP2270141A4 (de) Lacritin-teilpeptid
HK1134911A1 (en) Medicament for the treatment of endometriosis
ZA201200420B (en) Method for the purification of protein complexes
GB0724953D0 (en) Methods of peptide modification
EP2262594A4 (de) Reinigungsgeschoss und betriebsverfahren dafür

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110823

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/00 20060101ALI20121107BHEP

Ipc: A61K 38/17 20060101AFI20121107BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20121120

17Q First examination report despatched

Effective date: 20131025

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20141030

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150310